common.study.topics.clinical

Treatment of Metastatic Prostate Cancer

common.study.values.description

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate and prednisone (AA-P) compared to AA-P plus placebo.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Recruiting patients only common.study.methods.is-healthy-yes

Drug - Niraparib

Participants will receive niraparib 200 mg (2 capsules of 100 mg each) capsules once daily.

Drug - Abiraterone Acetate

Participants will receive abiraterone acetate 1000 mg (4 tablets of 250 mg each) tablets once daily.

Drug - Prednisone

Participants will receive prednisone 10 mg (2 tablets of 5 mg each) tablets daily.

Drug - Placebo

Participants will receive matching placebo capsules once daily.

participant.views.study.view.additional

participant.views.study.view.scientific-title

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer

common.study.values.clinical-trial-id

NCT03748641

participant.views.study.view.id

bkR6Xa